Trajan Wealth LLC Purchases 12,346 Shares of Cencora, Inc. $COR

Trajan Wealth LLC lifted its position in Cencora, Inc. (NYSE:COR) by 10.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 135,306 shares of the company’s stock after buying an additional 12,346 shares during the period. Cencora makes up about 1.8% of Trajan Wealth LLC’s investment portfolio, making the stock its 12th biggest position. Trajan Wealth LLC owned approximately 0.07% of Cencora worth $42,287,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Norges Bank purchased a new stake in shares of Cencora during the 2nd quarter valued at about $695,215,000. Mizuho Markets Americas LLC raised its position in Cencora by 116.4% in the third quarter. Mizuho Markets Americas LLC now owns 212,800 shares of the company’s stock worth $66,506,000 after acquiring an additional 1,511,906 shares during the period. Artisan Partners Limited Partnership purchased a new position in shares of Cencora during the 2nd quarter worth $411,888,000. Vanguard Group Inc. grew its position in shares of Cencora by 5.3% during the 2nd quarter. Vanguard Group Inc. now owns 22,479,041 shares of the company’s stock valued at $6,740,340,000 after acquiring an additional 1,125,661 shares during the period. Finally, Viking Global Investors LP increased its stake in shares of Cencora by 95.0% in the 2nd quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock worth $624,207,000 after purchasing an additional 1,013,913 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Stock Performance

NYSE COR opened at $360.70 on Monday. The company has a quick ratio of 0.51, a current ratio of 0.92 and a debt-to-equity ratio of 3.62. Cencora, Inc. has a twelve month low of $240.72 and a twelve month high of $377.54. The business has a 50-day moving average price of $349.41 and a 200-day moving average price of $331.39. The firm has a market cap of $70.17 billion, a price-to-earnings ratio of 43.35, a price-to-earnings-growth ratio of 1.68 and a beta of 0.68.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 EPS for the quarter, topping analysts’ consensus estimates of $4.04 by $0.04. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The company had revenue of $85.93 billion for the quarter, compared to analysts’ expectations of $86.12 billion. During the same period in the previous year, the firm earned $3.73 EPS. The firm’s revenue was up 5.5% compared to the same quarter last year. As a group, equities research analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, March 2nd. Investors of record on Friday, February 13th will be given a dividend of $0.60 per share. The ex-dividend date is Friday, February 13th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s dividend payout ratio is currently 28.85%.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Mizuho lifted their target price on Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Wells Fargo & Company raised their price objective on Cencora from $405.00 to $429.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 10th. TD Cowen lifted their price objective on Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Jefferies Financial Group upgraded Cencora from an “underperform” rating to a “buy” rating in a research note on Thursday, January 22nd. Finally, UBS Group raised their target price on shares of Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $399.00.

Insider Buying and Selling at Cencora

In other Cencora news, EVP Elizabeth S. Campbell sold 3,351 shares of Cencora stock in a transaction on Friday, December 19th. The shares were sold at an average price of $342.10, for a total value of $1,146,377.10. Following the sale, the executive vice president directly owned 23,891 shares in the company, valued at approximately $8,173,111.10. The trade was a 12.30% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Silvana Battaglia sold 1,677 shares of the stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $345.00, for a total transaction of $578,565.00. Following the transaction, the executive vice president directly owned 18,796 shares of the company’s stock, valued at $6,484,620. This trade represents a 8.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 15,220 shares of company stock worth $5,282,867. Insiders own 0.38% of the company’s stock.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.